ES2055845T3 - Composicion farmaceutica para el tratamiento de la osteoporosis. - Google Patents

Composicion farmaceutica para el tratamiento de la osteoporosis.

Info

Publication number
ES2055845T3
ES2055845T3 ES90120567T ES90120567T ES2055845T3 ES 2055845 T3 ES2055845 T3 ES 2055845T3 ES 90120567 T ES90120567 T ES 90120567T ES 90120567 T ES90120567 T ES 90120567T ES 2055845 T3 ES2055845 T3 ES 2055845T3
Authority
ES
Spain
Prior art keywords
treatment
pharmaceutical composition
osteoporosis
estrogen
thyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90120567T
Other languages
English (en)
Inventor
Tomoshi Nippon Zoki Phar Miura
Shinichiro Nippon Zoki Aonuma
Hiroyuki Nippon Zoki Pha Ohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2055845T3 publication Critical patent/ES2055845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPUESTO FARMACEUTICO PARA EL TRATAMIENTO DE OSTEOPOROSIS, COMPRENDE UN ESTREGENO Y UNA HORMONA DE TIROIDE COMO INGREDIENTES EFECTIVOS. UTILIZANDO EL ESTROGENO CON COMBINACION CON LA HORMONA DE TIROIDE, SE PUEDE OBTENER UNA ACTIVIDAD MUCHISIMO MAS GRANDE EN INCREMENTAR LA CANTIDAD DE HUESO QUE EN EL CASO DE SUMINISTRAR SOLAMENTE EL ESTROGENO.
ES90120567T 1989-10-26 1990-10-26 Composicion farmaceutica para el tratamiento de la osteoporosis. Expired - Lifetime ES2055845T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28114189 1989-10-26

Publications (1)

Publication Number Publication Date
ES2055845T3 true ES2055845T3 (es) 1994-09-01

Family

ID=17634937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90120567T Expired - Lifetime ES2055845T3 (es) 1989-10-26 1990-10-26 Composicion farmaceutica para el tratamiento de la osteoporosis.

Country Status (6)

Country Link
US (1) US5116828A (es)
EP (1) EP0424954B1 (es)
JP (1) JP3113269B2 (es)
AT (1) ATE104854T1 (es)
DE (1) DE69008476T2 (es)
ES (1) ES2055845T3 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123666T3 (es) * 1992-03-21 1999-01-16 Entec Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica.
CA2152163A1 (en) * 1992-12-29 1994-07-07 Michael F. Holick Use of vitamin d glycosides for the treatment or prevention of osteoporosis
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
IL108371A (en) * 1993-01-19 2009-09-01 Endorech Inc Use of sex steroid precursors to prepare medicaments for treatment of vaginal atrophy
US20030170290A1 (en) * 1993-06-16 2003-09-11 Shug Austin L. Delayed release carnitine
JPH09100293A (ja) * 1995-10-03 1997-04-15 Kanebo Ltd インターロイキン８の作用増強剤
US6236946B1 (en) 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6197291B1 (en) 1996-06-27 2001-03-06 Kanebo Limited Agent for potentiating the effect of interleukin-8
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
US7829552B2 (en) * 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
ES2523045T3 (es) * 2005-07-12 2014-11-20 Warner Chilcott Company, Llc Derivado éster de etinil estradiol
CN101228177A (zh) * 2005-07-12 2008-07-23 沃纳奇尔科特公司 雌二醇的3-酯前药
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
PL2206727T3 (pl) 2007-10-11 2015-08-31 Daiichi Sankyo Co Ltd Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami
JP2012520883A (ja) * 2009-03-16 2012-09-10 アイピントゥル，エルエルシー アルツハイマー病及び骨粗鬆症の治療並びに老化の軽減
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6434M (es) * 1967-02-23 1968-11-04
US4041022A (en) * 1967-05-24 1977-08-09 Ciba-Geigy Corporation Process for the manufacture of thyrocalcitonin
GB2138286B (en) * 1983-04-19 1986-10-08 Dr Christopher Harry Mortimer Pharmaceutical composition for the treatment of hair loss
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPS6089422A (ja) * 1983-10-24 1985-05-20 Kureha Chem Ind Co Ltd 抗骨粗鬆症剤
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US5001118A (en) * 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
JP2542846B2 (ja) * 1987-05-22 1996-10-09 日本臓器製薬株式会社 糖尿病治療剤
US4946679A (en) * 1988-07-25 1990-08-07 Thys Jacobs Susan Method for the treatment of premenstrual syndrome
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome

Also Published As

Publication number Publication date
DE69008476D1 (de) 1994-06-01
EP0424954B1 (en) 1994-04-27
US5116828A (en) 1992-05-26
DE69008476T2 (de) 1994-09-01
JP3113269B2 (ja) 2000-11-27
EP0424954A1 (en) 1991-05-02
JPH03209328A (ja) 1991-09-12
ATE104854T1 (de) 1994-05-15

Similar Documents

Publication Publication Date Title
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
IL92007A0 (en) Pharmaceutical compositions containing gestodene
ATE79271T1 (de) Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.
GR3002487T3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
BR9403783A (pt) Uso de uma composição cosmética
EP0289314A3 (en) Use of igf-ii in the treatment of bone disorders
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
ZA882151B (en) Binding inducing compositions
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
MX170055B (es) , "composicion insecticida y procedimiento para su obtencion
ZA935086B (en) Skin regenerating cosmetic composition
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
GR3001277T3 (en) Chlorpheniramine therapy
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
AR241632A1 (es) Procedimiento para preparar una composicion farmaceutica liquida de una 4-aroilimidazol-2-ona.
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 424954

Country of ref document: ES